The role of antimalarial agents in the treatment of SLE and lupus nephritis

Nature Reviews Nephrology

Volumn 7, Issue 12, 2011, Pages 718-729

  Lee, Senq J ^a   Silverman, Earl ^a   Bargman, Joanne M ^b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; CASPASE 3; CHLOROQUINE; CYTOKINE; GLUCOSE; HYDROXYCHLOROQUINE; MEPACRINE; METALLOPROTEINASE; PROSTAGLANDIN; TOLL LIKE RECEPTOR;

ANTIGEN PRESENTING CELL; APLASTIC ANEMIA; ATHEROSCLEROSIS; ATRIOVENTRICULAR BLOCK; CARDIOMYOPATHY; CLINICAL EFFECTIVENESS; CYTOKINE PRODUCTION; DIARRHEA; DRUG EFFICACY; DRUG EXCRETION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; DYSLIPIDEMIA; ENZYME ACTIVATION; ENZYME ACTIVITY; FABRY DISEASE; GLUCOSE TOLERANCE; HEART MUSCLE CONDUCTION DISTURBANCE; HEMOLYSIS; HUMAN; HYPERPIGMENTATION; HYPERTRANSAMINASEMIA; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE ACTIVATION; LEUKOPENIA; LUPUS ERYTHEMATOSUS NEPHRITIS; MALARIA; MALARIA CONTROL; MYOPATHY; NAUSEA AND VOMITING; NEOPLASM; NONHUMAN; OTOTOXICITY; PREGNANCY OUTCOME; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PSORIASIS; PSYCHOSIS; RENAL PROTECTION; RETINOPATHY; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; TREATMENT OUTCOME; URTICARIA;

ANTIMALARIALS; BIOMEDICAL RESEARCH; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS;

EID: 82355175246     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2011.150     Document Type: Review

References (119)

1. Schmajuk, G., Yazdany, J., Trupin, L. & Yelin, E. Hydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus. Arthritis Care Res. (Hoboken) 62, 386-392 (2010).
2. Ruiz-Irastorza, G., Ramos-Casals, M., Brito-Zeron, P. & Khamashta, M. A. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann. Rheum. Dis. 69, 20-28 (2010).
3. Wallace, D. J. The history of antimalarials. Lupus 5 (Suppl. 1), S2-S3 (1996). (Pubitemid 26196733)
4. Tett, S. E., Cutler, D. J., Day, R. O. & Brown, K. F. Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br. J. Clin. Pharmacol. 27, 771-779 (1989). (Pubitemid 19179515)
5. Furst, D. E. Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus 5 (Suppl. 1), S11-S15 (1996). (Pubitemid 26196735)
6. Kalia, S. & Dutz, J. P. New concepts in antimalarial use and mode of action in dermatology. Dermatol. Ther. 20, 160-174 (2007). (Pubitemid 350029307)
7. McChesney, E. W. Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. Am. J. Med. 75, 11-18 (1983). (Pubitemid 13025975)
8. Leecharoen, S., Wangkaew, S. & Louthrenoo, W. Ocular side effects of chloroquine in patients with rheumatoid arthritis, systemic lupus erythematosus and scleroderma. J. Med. Assoc. Thai. 90, 52-58 (2007).
9. Barré, P. E., Gascon-Barré, M., Meakins, J. L. & Goltzman, D. Hydroxychloroquine treatment of hypercalcemia in a patient with sarcoidosis undergoing hemodialysis. Am. J. Med. 82, 1259-1262 (1987).
10. Fox, R. Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development. Lupus 5 (Suppl. 1), S4-S10 (1996). (Pubitemid 26196734)
11. Ermann, J. & Bermas, B. L. The biology behind the new therapies for SLE. Int. J. Clin. Pract. 61, 2113-2119 (2007). (Pubitemid 350077396)
12. van den Borne, B. E., Dijkmans, B. A., de Rooij, H. H., le Cessie, S. & Verweij, C. L. Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. J. Rheumatol. 24, 55-60 (1997). (Pubitemid 27059858)
13. Karres, I. et al. Chloroquine inhibits proinflammatory cytokine release into human whole blood. Am. J. Physiol. 274, R1058-R1064 (1998). (Pubitemid 28217758)
14. Wozniacka, A., Lesiak, A., Narbutt, J., McCauliffe, D. P. & Sysa-Jedrzejowska, A. Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients. Lupus 15, 268-275 (2006). (Pubitemid 43828802)
15. Jang, C. H., Choi, J. H., Byun, M. S. & Jue, D. M. Chloroquine inhibits production of TNF-alpha, IL-1beta and IL-6 from lipopolysaccharide- stimulated human monocytes/macrophages by different modes. Rheumatology (Oxford) 45, 703-710 (2006).
16. Jeong, J. Y. & Jue, D. M. Chloroquine inhibits processing of tumor necrosis factor in lipopolysaccharide-stimulated RAW 264.7 macrophages. J. Immunol. 158, 4901-4907 (1997).
17. Sperber, K. et al. Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells. J. Rheumatol. 20, 803-808 (1993). (Pubitemid 23158473)
18. Weber, S. M., Chen, J. M. & Levitz, S. M. Inhibition of mitogen-activated protein kinase signaling by chloroquine. J. Immunol. 168, 5303-5309 (2002). (Pubitemid 34495999)
19. Löffler, B. M., Bohn, E., Hesse, B. & Kunze, H. Effects of antimalarial drugs on phospholipase A and lysophospholipase activities in plasma membrane, mitochondrial, microsomal and cytosolic subcellular fractions of rat liver. Biochim. Biophys. Acta 835, 448-455 (1985). (Pubitemid 15247856)
20. Kim, W. U. et al. Hydroxychloroquine potentiates Fas-mediated apoptosis of rheumatoid synoviocytes. Clin. Exp. Immunol. 144, 503-511 (2006).
21. Potvin, F., Petitclerc, E., Marceau, F. & Poubelle, P. E. Mechanisms of action of antimalarials in inflammation: induction of apoptosis in human endothelial cells. J. Immunol. 158, 1872-1879 (1997). (Pubitemid 127469546)
22. Wozniacka, A. et al. The influence of antimalarial treatment on IL-1beta, IL-6 and TNF-alpha mRNA expression on UVB-irradiated skin in systemic lupus erythematosus. Br. J. Dermatol. 159, 1124-1130 (2008).
23. Hurst, N. P., French, J. K., Gorjatschko, L. & Betts, W. H. Studies on the mechanism of inhibition of chemotactic tripeptide stimulated human neutrophil polymorphonuclear leucocyte superoxide production by chloroquine and hydroxychloroquine. Ann. Rheum. Dis. 46, 750-756 (1987). (Pubitemid 17140297)
24. Nguyen, T. Q., Capra, J. D. & Sontheimer, R. D. 4-Aminoquinoline antimalarials enhance UV-B induced c-jun transcriptional activation. Lupus 7, 148-153 (1998). (Pubitemid 28190677)
25. Lesiak, A. et al. Effect of chloroquine phosphate treatment on serum MMP-9 and TIMP-1 levels in patients with systemic lupus erythematosus. Lupus 19, 683-688 (2010).
26. Lim, E. J. et al. Toll-like receptor 9 dependent activation of MAPK and NF-kB is required for the CpG ODN-induced matrix metalloproteinase-9 expression. Exp. Mol. Med. 39, 239-245 (2007).
27. Wallace, D. J., Linker-Israeli, M., Metzger, A. L. & Stecher, V. J. The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. Lupus 2 (Suppl. 1), S13-S15 (1993). (Pubitemid 23103841)
28. Toubi, E. et al. The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus. Scand. J. Immunol. 63, 299-303 (2006).
29. Dubois, E. L. Antimalarials in the management of discoid and systemic lupus erythematosus. Semin. Arthritis Rheum. 8, 33-51 (1978). (Pubitemid 9021790)
30. Dubois, E. L. Quinacrine (atabrine) in treatment of systemic and discoid lupus erythematosus. AMA Arch. Intern. Med. 94, 131-141 (1954).
31. Rudnicki, R. D., Gresham, G. E. & Rothfield, N. F. The efficacy of antimalarials in systemic lupus erythematosus. J. Rheumatol. 2, 323-330 (1975).
32. [No authors listed] A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. N. Engl. J. Med. 324, 150-154 (1991).
33. Meinão, I. M., Sato, E. I., Andrade, L. E., Ferraz, M. B. & Atra, E. Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. Lupus 5, 237-241 (1996). (Pubitemid 26197484)
34. Alarcón, G. S. et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann. Rheum. Dis. 66, 1168-1172 (2007). (Pubitemid 47309732)
35. Fessler, B. J. et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 52, 1473-1480 (2005).
36. Molad, Y. et al. Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort. Lupus 11, 356-361 (2002). (Pubitemid 34760633)
37. Shinjo, S. K. et al. Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum. 62, 855-862 (2010).
38. Westlake, S. L. & Edwards C. J. Anti-malarials and lupus in West Africa use and lupus in Africans. Lupus 18, 193-195 (2009).
39. Hodis, H. N., Quismorio, F. P. Jr, Wickham, E. & Blankenhorn, D. H. The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus. J. Rheumatol. 20, 661-665 (1993). (Pubitemid 23138855)
40. Petri, M., Lakatta, C., Magder, L. & Goldman, D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am. J. Med. 96, 254-259 (1994). (Pubitemid 24099225)
41. Tam, L. S., Gladman, D. D., Hallett, D. C., Rahman, P. & Urowitz, M. B. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J. Rheumatol. 27, 2142-2145 (2000).
42. Borba, E. F. & Bonfá, E. Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J. Rheumatol. 28, 780-785 (2001). (Pubitemid 32246946)
43. Sachet, J. C. et al. Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients. Lupus 16, 273-278 (2007). (Pubitemid 46797891)
44. Cardoso, C. R., Signorelli, F. V., Papi, J. A. & Salles, G. F. Prevalence and factors associated with dyslipoproteinemias in Brazilian systemic lupus erythematosus patients. Rheumatol. Int. 28, 323-327 (2008).
45. Bevan, A. P., Christensen, J. R., Tikerpae, J. & Smith, G. D. Chloroquine augments the binding of insulin to its receptor. Biochem. J. 311, 787-795 (1995).
46. Petri, M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus 5 (Suppl. 1), S16-S22 (1996). (Pubitemid 26196736)
47. Rekedal, L. R. et al. Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases. Arthritis Rheum. 62, 3569-3573 (2010).
48. Penn, S. K. et al. Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. J. Rheumatol. 37, 1136-1142 (2010).
49. Gerstein, H. C., Thorpe, K. E., Taylor, D. W. & Haynes, R. B. The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas-a randomzed trial. Diabetes Res. Clin. Pract. 55, 209-219 (2002). (Pubitemid 34163292)
50. Bellomio, V. et al. Metabolic syndrome in Argentinean patients with systemic lupus erythematosus. Lupus 18, 1019-1025 (2009).
51. Razani, B., Feng, C. & Semenkovich, C. F. p53 is required for chloroquine-induced atheroprotection but not insulin sensitization. J. Lipid Res. 51, 1738-1746 (2010).
52. Roman, M. J. et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349, 2399-2406 (2003). (Pubitemid 37542988)
53. Zhang, C. Y. et al. Evaluation of risk factors that contribute to high prevalence of premature atherosclerosis in Chinese premenopausal systemic lupus erythematosus patients. J. Clin. Rheumatol. 15, 111-116 (2009).
54. Souza, A. W., Hatta, F. S., Miranda, F. Jr & Sato, E. I. Atherosclerotic plaque in carotid arteries in systemic lupus erythematosus: frequency and associated risk factors. Sao Paulo Med. J. 123, 137-142 (2005). (Pubitemid 40990717)
55. Von Feldt, J. M. et al. Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus. Arthritis Rheum. 54, 2220-2227 (2006). (Pubitemid 44051078)
56. Selzer, F. et al. Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus. Arthritis Rheum. 50, 151-159 (2004). (Pubitemid 38084299)
57. Selzer, F. et al. Vascular stiffness in women with systemic lupus erythematosus. Hypertension 37, 1075-1082 (2001). (Pubitemid 32304007)
58. Tanay, A. et al. Vascular elasticity of systemic lupus erythematosus patients is associated with steroids and hydroxychloroquine treatment. Ann. NY Acad. Sci. 1108, 24-34 (2007). (Pubitemid 47528715)
59. Bessant, R. et al. Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: a case-control study. Arthritis Rheum. 55, 892-899 (2006). (Pubitemid 44917462)
60. Urowitz, M. B. et al. Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res. (Hoboken) 62, 881-887 (2010).
61. Ruiz-Irastorza, G. et al. Antimalarials may influence the risk of malignancy in systemic lupus erythematosus. Ann. Rheum. Dis. 66, 815-817 (2007). (Pubitemid 46846704)
62. Sisó, A. et al. Previous antimalarial therapy in patients diagnosed with lupus nephritis: Influence on outcomes and survival. Lupus 17, 281-288 (2008). (Pubitemid 351655794)
63. Ruiz-Irastorza, G. et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 15, 577-583 (2006). (Pubitemid 44661744)
64. Jung, H. et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum. 62, 863-868 (2010).
65. Tsakonas, E. et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus 7, 80-85 (1998). (Pubitemid 28107971)
66. Pons-Estel, G. J. et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum. 61, 830-839 (2009).
67. Vlad, S. C. Protective effect of hydroxychloroquine on renal damage may be biased: comment on the article by Pons-Estel et al. Arthritis Rheum. 61, 1614 (2009).
68. Vinet, E., Bernatsky, S. & Suissa, S. Have some beneficial effects of hydroxychloroquine been overestimated? Potential biases in observational studies of drug effects: comment on the article by Pons-Estel et al. Arthritis Rheum. 61, 1614-1615 (2009).
69. Kasitanon, N., Fine, D. M., Haas, M., Magder, L. S. & Petri, M. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus 15, 366-370 (2006). (Pubitemid 44032712)
70. Parke, A. Antimalarial drugs and pregnancy. Am. J. Med. 85, 30-3 (1988).
71. Parke, A. & West, B. Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. J. Rheumatol. 23, 1715-1718 (1996). (Pubitemid 26342440)
72. Costedoat-Chalumeau, N., Amoura, Z., Huong, D. L., Lechat, P. & Piette, J. C. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature. Autoimmun. Rev. 4, 111-115 (2005). (Pubitemid 40255619)
73. Germain, S. & Nelson-Piercy, C. Lupus nephritis and renal disease in pregnancy. Lupus 15, 148-155 (2006).
74. Clowse, M. E., Magder, L., Witter, F. & Petri, M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 54, 3640-3647 (2006). (Pubitemid 44737176)
75. Levy, R. A. et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 10, 401-404 (2001). (Pubitemid 32578614)
76. Izmirly, P. M. et al. Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann. Rheum. Dis. 69, 1827-1830 (2010).
77. Wang, C. et al. Discontinuation of antimalarial drugs in systemic lupus erythematosus. J. Rheumatol. 26, 808-815 (1999). (Pubitemid 29195667)
78. Sundelin, S. P. & Terman, A. Different effects of chloroquine and hydroxychloroquine on lysosomal function in cultured retinal pigment epithelial cells. APMIS 110, 481-489 (2002). (Pubitemid 34856490)
79. Marmor, M. F., Kellner, U., Lai, T. Y., Lyons, J. S. & Meiler, W. F. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 118, 415-422 (2011).
80. Rynes, R. I. Ophthalmologic considerations in using antimalarials in the United States. Lupus 5 (Suppl. 1), S73-S74 (1996). (Pubitemid 26196748)
81. Spalton, D. J. Retinopathy and antimalarial drugs-the British experience. Lupus 5 (Suppl. 1), S70-S72 (1996). (Pubitemid 26196747)
82. Marmor, M. F., Carr, R. E., Easterbrook, M., Farjo, A. A. & Mieler, W. F. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology 109, 1377-1382 (2002). (Pubitemid 34700934)
83. Mavrikakis, I. et al. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmology 110, 1321-1326 (2003). (Pubitemid 36842465)
84. Lyons, J. S. & Severns, M. L. Using multifocal ERG ring ratios to detect and follow Plaquenil retinal toxicity: a review: review of mfERG ring ratios in Plaqunil toxicity. Doc. Ophthal. 118, 29-36 (2008).
85. Wolfe, F. & Marmor, M. F. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res. (Hoboken) 62, 775-784 (2010).
86. Levy, G. D. et al. Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. Arthritis Rheum. 40, 1482-1486 (1997). (Pubitemid 27430960)
87. The Royal College of Ophthalmologists. Hydroxychloroquine and Ocular Toxicity Recommendations on Screening [online], http://www.rcophth.ac.uk/core/ core-picker/download.asp?id=165&filetitle= Ocular+Toxicity+and+Hydroxychloroquine%3A+Guidelines+for+Screening+2009 (2009).
88. Nord, J. E., Shah, P. K., Rinaldi, R. Z. & Weisman, M. H. Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature. Semin. Arthritis Rheum. 33, 336-351 (2004). (Pubitemid 38496042)
89. Puri, P. K., Lountzis, N. I., Tyler, W. & Ferringer, T. Hydroxychloroquine-induced hyperpigmentation: the staining pattern. J. Cutan. Pathol. 35, 1134-1137 (2008).
90. Herman, S. M., Shin, M. H., Holbrook, A. & Rosenthal, D. The role of antimalarials in the exacerbation of psoriasis: a systematic review. Am. J. Clin. Dermatol. 7, 249-257 (2006).
91. Bracamonte, E. R., Kowalewska, J., Starr, J., Gitomer, J. & Alpers, C. E. Iatrogenic phospholipidosis mimicking Fabry disease. Am. J. Kidney Dis. 48, 844-850 (2006). (Pubitemid 44740050)
92. Costedoat-Chalumeau, N. et al. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann. Rheum. Dis. 66, 821-824 (2007). (Pubitemid 46846706)
93. Costedoat-Chalumeau, N. et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum. 54, 3284-3290 (2006). (Pubitemid 44622099)
94. Calvo-Alén, J. et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study. Ann. Rheum. Dis. 65, 785-790 (2006). (Pubitemid 43799179)
95. James, J. A. et al. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus 16, 401-409 (2007). (Pubitemid 47122213)
96. Ruiz-Irastorza, G. et al. Predictors of major infections in systemic lupus erythematosus. Arthritis Res. Ther. 11, R109 (2009).
97. Shinjo, S. K. Systemic lupus erythematosus in the elderly: antimalarials in disease remission. Rheumatol. Int. 29, 1087-1090 (2009).
98. Pons-Estel, G. J. et al. Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort. Arthritis Care Res. (Hoboken) 62, 393-400 (2010).
99. de Leeuw, K. et al. Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus. Lupus 15, 675-682 (2006). (Pubitemid 44682830)
100. Choojitarom, K. et al. Lupus nephritis and Raynaud's phenomenon are significant risk factors for vascular thrombosis in SLE patients with positive antiphospholipid antibodies. Clin. Rheumatol. 27, 345-351 (2008).
101. Kaiser, R., Cleveland, C. M. & Criswell, L. A. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann. Rheum. Dis. 68, 238-241 (2009).
102. Tektonidou, M. G., Laskari, K., Panagiotakos, D. B. & Moutsopoulos, H. M. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum. 61, 29-36 (2009).
103. Barber, C. E., Geldenhuys, L. & Hanly, J. G. Sustained remission of lupus nephritis. Lupus 15, 94-101 (2006). (Pubitemid 43345334)
104. Buchanan, N. M. et al. Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. Ann. Rheum. Dis. 55, 486-488 (1996). (Pubitemid 26249027)
105. Costedoat-Chalumeau, N. et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum. 48, 3207-3211 (2003). (Pubitemid 37409333)
106. Carvalheiras, G. et al. Pregnancy and systemic lupus erythematosus: review of clinical features and outcome of 51 pregnancies at a single institution. Clin. Rev. Allergy Immunol. 38, 302-306 (2010).
107. Aviña-Zubieta, J. A., Galindo-Rodriguez, G., Newman, S., Suarez-Almazor, M. E. & Russell, A. S. Long-term effectiveness of antimalarial drugs in rheumatic diseases. Ann. Rheum. Dis. 57, 582-587 (1998). (Pubitemid 28513135)
108. Finbloom, D. S., Silver, K., Newsome, D. A. & Gunkel, R. Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity. J. Rheumatol. 12, 692-694 (1985). (Pubitemid 15229659)
109. Spalton, D. J., Verdon Roe, G. M. & Hughes, G. R. Hydroxychloroquine, dosage parameters and retinopathy. Lupus 2, 355-358 (1993). (Pubitemid 24017334)
110. Morand, E. F., McCloud, P. I. & Littlejohn, G. O. Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis. Ann. Rheum. Dis. 51, 1318-1321 (1992). (Pubitemid 23000068)
111. Costedoat-Chalumeau, N. et al. Cardiomyopathy related to antimalarial therapy with illustrative case report. Cardiology 107, 73-80 (2007).
112. Costedoat-Chalumeau, N. et al. Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases. Rheumatology (Oxford) 46, 808-810 (2007). (Pubitemid 47061713)
113. Wozniacka, A., Cygankiewicz, I., Chudzik, M., Sysa-Jedrzejowska, A. & Wranicz, J. K. The cardiac safety of chloroquine phosphate treatment in patients with systemic lupus erythematosus: the influence on arrhythmia, heart rate variability and repolarization parameters. Lupus 15, 521-525 (2006). (Pubitemid 44289550)
114. Cervera, A., Espinosa, G., Font, J. & Ingelmo, M. Cardiac toxicity secondary to long term treatment with chloroquine. Ann. Rheum. Dis. 60, 301 (2001). (Pubitemid 32260621)
115. Di Giacomo, T. B., Valente, N. Y. & Nico, M. M. Chloroquine-induced hair depigmentation. Lupus 18, 264-266 (2009).
116. Bezerra, E. L., Vilar, M. J., da Trindade Neto, P. B. & Sato, E. L. Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus. Arthritis Rheum. 52, 3073-3078 (2005). (Pubitemid 41447088)
117. Van Beek, M. J. & Piette, W. W. Antimalarials. Dermatol. Clin. 19, 147-160 (2001). (Pubitemid 32038052)
118. Casado, E. et al. Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients. Ann. Rheum. Dis. 65, 385-390 (2006). (Pubitemid 43268230)
119. Collins, G. B. & McAllister, M. S. Chloroquine psychosis masquerading as PCP: a case report. J. Psychoactive Drugs 40, 211-214 (2008).